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Concurrent chemoradiation therapy has been the standard treatment in locally advanced cervical cancer since 1999. In a homo-
geneous series of 288 patients treated between 1996 and December 2011, survival data, prognostic factors and toxicity of the
treatment have been analyzed. The treatment includes external beam radiotherapy and brachytherapy, concurrent weekly
chemotherapy. Median age of the patients is 54 years old. FIGO classiﬁcation for disease stages shows 6.1% (IB1), 14.6% (IB2),
47.1% (IIB), 24.4% (III), 7.8% (IVA). Squamous cell carcinoma was the most common histology (77.4%), followed by adenocarci-
noma in 16.8%. After a median follow-up of 4.4 years, the 5-year overall survival rate is 80.2%. By diagnostic stage, they are 85%
in IB2, 76% in IIB, 70% in III, and 68% in IVA. The main location for recurrence is the cervix (11.8%), and the most common site
for distant disease is the lung (4.8%). 24.4% have local and distant recurrence. In the multivariate analysis, the prognostic factors
for overall survival that have been identiﬁed with a statistical signiﬁcance are HPV and HIV infection, high stages of disease
and older patients. Performance status≥1 and brachytherapy have only a signiﬁcant value in the univariate analysis. The acute
toxicity grade≥3 was observed in 19.4% of patients (14.1% haematological). The most frequent low grade toxicity was 46.3%
haematological, 40% of bowel-related toxicity, 38.9% of nausea and vomiting, and 8.1% of renal dysfunction. Chronic toxicity
grade≥3 has been only seen in 1.2% (renal dysfunction), and in the low grades, it is observed a 6% of bowel-related toxicity and
1.4% of mild renal dysfunction. This long follow-up series shows a good overall survival rate with chemoradiation therapy in
locally advanced stages of cervical cancer, with a low rate of acute and, especially, chronic toxicity, indicating a good quality of
life for these patients.
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Background. High-Dose-Rate Brachytherapy (HDR-BT) is an accepted part of treatment for endometrial carcinoma and is usually
performed in 1–2 fractions per week using different total doses and doses per fraction. To reduce the overall treatment time,
HDR-BT was administered with a 3–4 days/week schedule.
Patients and methods. From June 2003 to December 2008, 164 patients with stage I–IIIc endometrial carcinoma were treated with
HDR-BT (4-5Gy per fraction). The patients were divided into 2 groups; Group 1 (40/164 patients) was treated with HDR-BT alone
(6 fractions; 4fr/week) and Group 2 (124/164 patients) was treated with both (External Beam Radiotherapy [EBRT] +HDR-BT: 3
fractions/week). Complications were analysed using RTOG scores for rectum and bladder and the objective scores of LENT-SOMA
for vaginal complications.
Results. The mean follow-up was 48 months. In group 1, 35% of patients underwent treatment in <10 days and 65% in >10 days. In
group 2, 53.2% received treatment in <5 days and in 46.8% in >5 days. Vaginal relapse was observed in only 2 patients (1.2%), both
having received adjuvant EBRT+HDR-BT. Acute vaginal toxicity appeared in 8.5% and late vaginal toxicity in 20.7% of patients,
with 13.4% being G1, 6.7% G2 and only 0.6% being G4. No statistically signiﬁcant differences were found in complications in either
brachytherapy group regardless of the overall time.
Conclusion. In our series three fractions given in 3–5/days after EBRT or 6 fractions in 10 days, is a safe regimen in terms of
complications and local control.
http://dx.doi.org/10.1016/j.rpor.2013.03.230
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Introduction. To evaluate outcome, failure patterns, prognostic factors and radiotherapy (RT) toxicity after postoperative RT for
Stages I-III EC in Tarragona Province (Spain).
Methods and materials. A retrospective population-based review was conducted on 251 patients with stages I–III EC (excluding
sarcoma cases) treated between 1997 and 2006 from different gynaecological Departments and in a single Radiation Oncology
institution. Multivariate analysis of variables was performed for the endpoints of overall survival (OS), disease-free survival (DFS)
and locoregional relapse free survival (LRFS).
